Brown Julie, Farquhar Cindy
The Liggins Institute and Department of Obstetrics and Gynaecology, University of Auckland, FMHS, Auckland, New Zealand.
Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD009590. doi: 10.1002/14651858.CD009590.pub2.
This overview reports on interventions for pain relief and for subfertility in pre-menopausal women with clinically diagnosed endometriosis.
The objective of this overview was to summarise the evidence from Cochrane systematic reviews on treatment options for women with pain or subfertility associated with endometriosis.
Published Cochrane systematic reviews reporting pain or fertility outcomes in women with clinically diagnosed endometriosis were eligible for inclusion in the overview. We also identified Cochrane reviews in preparation (protocols and titles) for future inclusion. The reviews, protocols and titles were identified by searching the Cochrane Database of Systematic Reviews and Archie (the Cochrane information management system) in March 2014.Pain-related outcomes of the overview were pain relief, clinical improvement or resolution and pain recurrence. Fertility-related outcomes were live birth, clinical pregnancy, ongoing pregnancy, miscarriage and adverse events.Selection of systematic reviews, data extraction and quality assessment were undertaken in duplicate. Review quality was assessed using the AMSTAR tool. The quality of the evidence for each outcome was assessed using GRADE methods. Review findings were summarised in the text and the data for each outcome were reported in 'Additional tables'.
Seventeen systematic reviews published in The Cochrane Library were included. All the reviews were high quality. The quality of the evidence for specific comparisons ranged from very low to moderate. Limitations in the evidence included risk of bias in the primary studies, inconsistency between the studies, and imprecision in effect estimates. Pain relief (14 reviews) Gonadotrophin-releasing hormone (GnRH) analogues One systematic review reported low quality evidence of an overall benefit for GnRH analogues compared with placebo or no treatment. Ovulation suppression Five systematic reviews reported on medical treatment using ovulation suppression. There was moderate quality evidence that the levonorgestrel-releasing intrauterine system (LNG-IUD) was more effective than expectant management, and very low quality evidence that danazol was more effective than placebo. There was no consistent evidence of a difference in effectiveness between oral contraceptives and goserelin, estrogen plus progestogen and placebo, or progestogens and placebo, though in all cases the relevant evidence was of low or very low quality. Non-steroidal anti-inflammatory drugs (NSAIDS)A review of NSAIDs reported inconclusive evidence of a benefit in symptom relief compared with placebo. Surgical interventions There were two reviews of surgical interventions. One reported moderate quality evidence of a benefit in pain relief following laparoscopic surgery compared to diagnostic laparoscopy only. The other reported very low quality evidence that recurrence rates of endometriomata were lower after excisional surgery than after ablative surgery. Post-surgical medical interventions Two reviews reported on post-surgical medical interventions. Neither found evidence of an effect on pain outcomes, though in both cases the evidence was of low or very low quality. Alternative medicine There were two systematic reviews of alternative medicine. One reported evidence of a benefit from auricular acupuncture compared to Chinese herbal medicine, and the other reported no evidence of a difference between Chinese herbal medicine and danazol. In both cases the evidence was of low or very low quality. Anti-TNF-α drugs One review found no evidence of a difference in effectiveness between anti-TNF-α drugs and placebo. However, the evidence was of low quality. Reviews reporting fertility outcomes (8 reviews) Medical interventions Four reviews reported on medical interventions for improving fertility in women with endometriosis. One compared three months of GnRH agonists with a control in women undergoing assisted reproduction and found very low quality evidence of an increase in clinical pregnancies in the treatment group. There was no evidence of a difference in effectiveness between the interventions in the other three reviews, which compared GnRH agonists versus antagonists, ovulation suppression versus placebo or no treatment, and pre-surgical medical therapy versus surgery alone. In all cases the evidence was of low or very low quality. Surgical interventions Three reviews reported on surgical interventions. There was moderate quality evidence that both live births or ongoing pregnancy rates and clinical pregnancy rates were higher after laparoscopic surgery than after diagnostic laparoscopy alone. There was low quality evidence of no difference in effectiveness between surgery and expectant management for endometrioma. One review found low quality evidence that excisional surgery resulted in higher clinical pregnancy rates than drainage or ablation of endometriomata. Post-surgical interventions Two reviews reported on post-surgical medical interventions. They found no evidence of an effect on clinical pregnancy rates. The evidence was of low or very low quality. Alternative medicine A review of Chinese herbal medicine in comparison with gestrinone found no evidence of a difference between the groups in clinical pregnancy rates. However, the evidence was of low quality. Adverse events Reviews of GnRH analogues and of danazol reported that the interventions were associated with higher rates of adverse effects than placebo; and depot progestagens were associated with higher rates of adverse events than other treatments. Chinese herbal medicine was associated with fewer side effects than gestrinone or danazol.Three reviews reported miscarriage as an outcome. No difference was found between surgical and diagnostic laparoscopy, between GnRH agonists and antagonists, or between aspiration of endometrioma and expectant management. However, in all cases the quality of the evidence was of low quality.
AUTHORS' CONCLUSIONS: For women with pain and endometriosis, suppression of menstrual cycles with gonadotrophin-releasing hormone (GnRH) analogues, the levonorgestrel-releasing intrauterine system (LNG-IUD) and danazol were beneficial interventions. Laparoscopic treatment of endometriosis and excision of endometriomata were also associated with improvements in pain. The evidence on NSAIDs was inconclusive. There was no evidence of benefit with post-surgical medical treatment.In women with endometriosis undergoing assisted reproduction, three months of treatment with GnRH agonist improved pregnancy rates. Excisional surgery improved spontaneous pregnancy rates in the nine to 12 months after surgery compared to ablative surgery. Laparoscopic surgery improved live birth and pregnancy rates compared to diagnostic laparoscopy alone. There was no evidence that medical treatment improved clinical pregnancy rates.Evidence on harms was scanty, but GnRH analogues, danazol and depot progestagens were associated with higher rates than other interventions.
本综述报告了针对临床诊断为子宫内膜异位症的绝经前女性的疼痛缓解和生育力低下的干预措施。
本综述的目的是总结Cochrane系统评价中关于子宫内膜异位症相关疼痛或生育力低下女性治疗选择的证据。
已发表的Cochrane系统评价报告了临床诊断为子宫内膜异位症女性的疼痛或生育结局,符合纳入本综述的条件。我们还确定了正在准备的Cochrane评价(方案和标题)以供未来纳入。通过检索2014年3月的Cochrane系统评价数据库和Archie(Cochrane信息管理系统)来识别这些评价、方案和标题。本综述与疼痛相关的结局为疼痛缓解、临床改善或缓解以及疼痛复发。与生育相关的结局为活产、临床妊娠、持续妊娠、流产和不良事件。系统评价的选择、数据提取和质量评估均进行了重复操作。使用AMSTAR工具评估评价质量。使用GRADE方法评估每个结局的证据质量。综述结果在正文中进行了总结,每个结局的数据在“附加表格”中报告。
纳入了发表在《Cochrane图书馆》中的17篇系统评价。所有评价质量都很高。特定比较的证据质量从极低到中等不等。证据的局限性包括原始研究中的偏倚风险、研究之间的不一致性以及效应估计的不精确性。疼痛缓解(14篇综述)促性腺激素释放激素(GnRH)类似物一项系统评价报告称,与安慰剂或不治疗相比,GnRH类似物总体获益的证据质量较低。排卵抑制五项系统评价报告了使用排卵抑制的药物治疗。有中等质量的证据表明,左炔诺孕酮宫内节育系统(LNG-IUD)比期待治疗更有效,而达那唑比安慰剂更有效的证据质量极低。口服避孕药与戈舍瑞林、雌激素加孕激素与安慰剂、或孕激素与安慰剂之间在有效性上没有一致的差异证据,尽管在所有情况下相关证据质量都很低或极低。非甾体抗炎药(NSAIDs)一项关于NSAIDs的综述报告称,与安慰剂相比,其在症状缓解方面的获益证据尚无定论。手术干预有两篇关于手术干预的综述。一篇报告称,与仅进行诊断性腹腔镜检查相比,腹腔镜手术后疼痛缓解有中等质量的证据。另一篇报告称,切除手术后子宫内膜瘤的复发率低于消融手术的证据质量极低。术后药物干预两篇综述报告了术后药物干预。两者均未发现对疼痛结局有影响的证据,尽管在两种情况下证据质量都很低或极低。替代医学有两篇关于替代医学的系统评价。一篇报告称,与中药相比,耳针有获益证据,另一篇报告称中药与达那唑之间没有差异证据。在两种情况下证据质量都很低或极低。抗TNF-α药物一项综述发现,抗TNF-α药物与安慰剂在有效性上没有差异证据。然而,证据质量很低。报告生育结局的综述(8篇综述)药物干预四项综述报告了改善子宫内膜异位症女性生育力的药物干预措施。一项研究比较了接受辅助生殖的女性使用三个月GnRH激动剂与对照组,发现治疗组临床妊娠增加有极低质量的证据。在其他三项综述中,干预措施之间没有有效性差异的证据,这些综述比较GnRH激动剂与拮抗剂、排卵抑制与安慰剂或不治疗、以及术前药物治疗与单独手术。在所有情况下证据质量都很低或极低。手术干预三项综述报告了手术干预措施。有中等质量的证据表明,腹腔镜手术后活产或持续妊娠率以及临床妊娠率均高于仅进行诊断性腹腔镜检查。对于子宫内膜瘤,手术与期待治疗在有效性上没有差异的证据质量很低。一篇综述发现,切除手术导致的临床妊娠率高于子宫内膜瘤引流或消融的证据质量很低。术后干预两篇综述报告了术后药物干预。他们未发现对临床妊娠率有影响的证据。证据质量很低或极低。替代医学一项比较中药与孕三烯酮的综述发现,两组在临床妊娠率上没有差异证据。然而,证据质量很低。不良事件关于GnRH类似物和达那唑的综述报告称,与安慰剂相比,这些干预措施的不良反应发生率更高;长效孕激素与其他治疗相比,不良事件发生率更高。中药的副作用比孕三烯酮或达那唑少。三项综述将流产作为结局。手术与诊断性腹腔镜检查、GnRH激动剂与拮抗剂、或子宫内膜瘤抽吸与期待治疗之间均未发现差异。然而,在所有情况下证据质量都很低。
对于患有疼痛和子宫内膜异位症的女性,使用促性腺激素释放激素(GnRH)类似物、左炔诺孕酮宫内节育系统(LNG-IUD)和达那唑抑制月经周期是有益的干预措施。腹腔镜治疗子宫内膜异位症和切除子宫内膜瘤也与疼痛改善相关。关于NSAIDs的证据尚无定论。术后药物治疗没有获益证据。在接受辅助生殖的子宫内膜异位症女性中,使用三个月GnRH激动剂治疗可提高妊娠率。与消融手术相比,切除手术在术后9至12个月可提高自然妊娠率。与仅进行诊断性腹腔镜检查相比,腹腔镜手术可提高活产和妊娠率。没有证据表明药物治疗可提高临床妊娠率。关于危害的证据较少,但GnRH类似物、达那唑和长效孕激素的不良反应发生率高于其他干预措施。